Castle Biosciences Hires Vice President Of Marketing

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment, today announced the appointment of Timothy Decker as Vice President of Marketing.

“We are extremely pleased to have Tim join our team and look forward to his contributions as we advance the commercialization of our high value prognostic tests.”

Mr. Decker will oversee global marketing strategy and tactical programs at Castle Biosciences. He joins the Company with over 25 years of experience in the molecular diagnostic, biotechnology, pharmaceutical and medical device industries in therapeutic areas spanning oncology, immunology, pulmonology, urology, cardiology, and rheumatology. Most recently, Mr. Decker served as Senior Director, Sales & Marketing, for Genomic Health, where he was instrumental in the strategic planning, sales and marketing of the company’s Oncotype DX^® Breast, Colon and Prostate Cancer assays. Previously, Mr. Decker held senior strategic marketing roles at Abbott Laboratories, last serving as Director of Marketing, Pulmonology, where he led highly successful commercialization expansion initiatives for its anti-RSV monoclonal antibody Synagis (palivizumab) in international markets.

Mr. Decker received a B.S. in Business Administration, cum laude, from the University of Colorado at Boulder and an M.B.A., magna cum laude, from the Thunderbird School of Global Management.

“Tim brings with him strong expertise in cancer genomics and an impressive track record of successfully launching commercial efforts around some of the most widely used cancer assays today in the U.S. and international markets,” said Derek Maetzold, President and CEO of Castle Biosciences. “We are extremely pleased to have Tim join our team and look forward to his contributions as we advance the commercialization of our high value prognostic tests.”

About Castle Biosciences

Castle Biosciences is a molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about their treatment and follow-up care based on the individual molecular signature of their tumor. The Company currently offers tests for patients with uveal melanoma (DecisionDx™-UM), cutaneous melanoma (DecisionDx™-Melanoma) and esophageal cancer (DecisionDx™-EC), among others. Castle Biosciences is based in Friendswood, TX (Houston), and has laboratory operations in Phoenix, AZ. More information can be found at www.castlebiosciences.com.

DecisionDx™-UM, DecisionDx™-Melanoma and DecisionDx™-EC are the trademarks of Castle Biosciences, Inc. Any other trademarks are the property of their respective owners.